Targeting KAT2A/B with an Oral Heterobifunctional Degrader for Heme Malignancies & Inflammatory Diseases

By | 23 June 2026
  • AUTX-703 is in phase 1 development for hematological malignancies
  • AUTX-163 for inflammatory diseases